Open AccessPembrolizumab and concurrent hypo-fractionated radiotherapy for advanced non-resectable cutaneous squamous cell carcinoma
Author(s) -
Justine Lavaud,
Astrid Blom,
Christine Longvert,
Magali Fort,
Elisa FunckBrentano,
Philippe Saïag
Publication year - 2019
Publication title -
european journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.48
H-Index - 71
eISSN - 1952-4013
pISSN - 1167-1122
DOI - 10.1684/ejd.2019.3671
Subject(s) - medicine , pembrolizumab , radiation therapy , basal cell , oncology , dermatology , cancer , immunotherapy
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent non-melanoma skin cancer. Treatment options for inoperable advanced cSCC cases are limited. The efficacy of anti-programmed cell death-1 (PD-1) monoclonal antibodies (mAb) has been reported recently in some patients with cSCC.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom